268 related articles for article (PubMed ID: 29592805)
1. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Tweed CD; Wills GH; Crook AM; Dawson R; Diacon AH; Louw CE; McHugh TD; Mendel C; Meredith S; Mohapi L; Murphy ME; Murray S; Murthy S; Nunn AJ; Phillips PPJ; Singh K; Spigelman M; Gillespie SH
BMC Med; 2018 Mar; 16(1):46. PubMed ID: 29592805
[TBL] [Abstract][Full Text] [Related]
2. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Watkins PB; Dube LM; Walton-Bowen K; Cameron CM; Kasten LE
Drug Saf; 2007; 30(9):805-15. PubMed ID: 17722971
[TBL] [Abstract][Full Text] [Related]
3. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
[TBL] [Abstract][Full Text] [Related]
4. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
5. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Tweed CD; Crook AM; Amukoye EI; Dawson R; Diacon AH; Hanekom M; McHugh TD; Mendel CM; Meredith SK; Murphy ME; Murthy SE; Nunn AJ; Phillips PPJ; Singh KP; Spigelman M; Wills GH; Gillespie SH
BMC Infect Dis; 2018 Jul; 18(1):317. PubMed ID: 29996783
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.
Xu HM; Chen Y; Xu J; Zhou Q
World J Gastroenterol; 2012 Nov; 18(41):5972-8. PubMed ID: 23139615
[TBL] [Abstract][Full Text] [Related]
7. Liver injury during antituberculosis treatment: an 11-year study.
Døssing M; Wilcke JT; Askgaard DS; Nybo B
Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
[TBL] [Abstract][Full Text] [Related]
8. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
Fountain FF; Tolley E; Chrisman CR; Self TH
Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.
Saito Z; Kaneko Y; Kinoshita A; Kurita Y; Odashima K; Horikiri T; Yoshii Y; Seki A; Seki Y; Takeda H; Kuwano K
BMC Infect Dis; 2016 Nov; 16(1):668. PubMed ID: 27835982
[TBL] [Abstract][Full Text] [Related]
10. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
Tolman KG; Freston JW; Kupfer S; Perez A
Drug Saf; 2009; 32(9):787-800. PubMed ID: 19670918
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
[TBL] [Abstract][Full Text] [Related]
12. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
13. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
[TBL] [Abstract][Full Text] [Related]
14. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
Arthritis Rheumatol; 2017 Sep; 69(9):1751-1761. PubMed ID: 28597609
[TBL] [Abstract][Full Text] [Related]
15. An official ATS statement: hepatotoxicity of antituberculosis therapy.
Saukkonen JJ; Cohn DL; Jasmer RM; Schenker S; Jereb JA; Nolan CM; Peloquin CA; Gordin FM; Nunes D; Strader DB; Bernardo J; Venkataramanan R; Sterling TR;
Am J Respir Crit Care Med; 2006 Oct; 174(8):935-52. PubMed ID: 17021358
[TBL] [Abstract][Full Text] [Related]
16. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
17. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection.
Fountain FF; Tolley EA; Jacobs AR; Self TH
Am J Med Sci; 2009 May; 337(5):317-20. PubMed ID: 19295414
[TBL] [Abstract][Full Text] [Related]
18. Marked Increase of Gamma-Glutamyltransferase as an Indicator of Drug-Induced Liver Injury in Patients without Conventional Diagnostic Criteria of Acute Liver Injury.
Weber S; Allgeier J; Denk G; Gerbes AL
Visc Med; 2022 Jun; 38(3):223-228. PubMed ID: 35814980
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced liver injury in hospitalized HIV patients: high incidence and association with drugs for tuberculosis.
Tomich LG; Núñez M; Mendes-Correa MC
Ann Hepatol; 2015; 14(6):888-94. PubMed ID: 26436361
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring.
Shamseddeen H; Vilar-Gomez E; Chalasani N; Myers RP; Subramanian GM; Shlevin HH; Allgood AE; Orman ES
Drug Saf; 2020 Mar; 43(3):281-290. PubMed ID: 31907854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
